| Year |
Citation |
Score |
| 2020 |
Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, Abdelkader H. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Delivery and Translational Research. PMID 32901367 DOI: 10.1007/S13346-020-00843-Z |
0.377 |
|
| 2020 |
Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Progress in Retinal and Eye Research. 100901. PMID 32891866 DOI: 10.1016/J.Preteyeres.2020.100901 |
0.39 |
|
| 2020 |
Patil MA, Kompella UB. Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. PMID 32552217 DOI: 10.1089/Jop.2020.0028 |
0.322 |
|
| 2019 |
Matter B, Ghaffari A, Bourne D, Wang Y, Choi S, Kompella UB. Dexamethasone Degradation in Aqueous Medium and Implications for Correction of In Vitro Release from Sustained Release Delivery Systems. Aaps Pharmscitech. 20: 320. PMID 31646399 DOI: 10.1208/S12249-019-1508-7 |
0.336 |
|
| 2019 |
Kompella UB, Domb A, Urtti A, Jayagopal A, Wilson CG, Tang-Liu D. Ocular Drug Delivery: Nanotechnology, Physical and Chemical Methods, Vitreous Drug Binding, and Aging Eye. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. PMID 31259643 DOI: 10.1089/Jop.2018.0138 |
0.371 |
|
| 2019 |
Damiati S, Scheberl A, Zayni S, Damiati SA, Schuster B, Kompella UB. Albumin-bound nanodiscs as delivery vehicle candidates: Development and characterization. Biophysical Chemistry. 251: 106178. PMID 31102749 DOI: 10.1016/J.Bpc.2019.106178 |
0.306 |
|
| 2019 |
Kompella UB. Clinical translation of eye drops and complex drug products Acta Ophthalmologica. 97. DOI: 10.1111/J.1755-3768.2019.8166 |
0.307 |
|
| 2018 |
Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artificial Cells, Nanomedicine, and Biotechnology. 1-8. PMID 30450979 DOI: 10.1080/21691401.2018.1528984 |
0.321 |
|
| 2018 |
Lenin R, Nagy PG, Alli S, Rao VR, Clauss MA, Kompella UB, Gangaraju R. Critical role of endoplasmic reticulum stress in chronic endothelial activation-induced visual deficits in tie2-tumor necrosis factor mice. Journal of Cellular Biochemistry. PMID 30054947 DOI: 10.1002/Jcb.27072 |
0.311 |
|
| 2018 |
Damiati S, Kompella UB, Damiati SA, Kodzius R. Microfluidic Devices for Drug Delivery Systems and Drug Screening. Genes. 9. PMID 29462948 DOI: 10.3390/Genes9020103 |
0.346 |
|
| 2017 |
Hartman RR, Kompella UB. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. PMID 29206556 DOI: 10.1089/Jop.2017.0121 |
0.344 |
|
| 2017 |
Lancina MG, Singh S, Kompella UB, Husain S, Yang H. Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery. Acs Biomaterials Science & Engineering. 3: 1861-1868. PMID 29152562 DOI: 10.1021/Acsbiomaterials.7B00319 |
0.382 |
|
| 2017 |
Tran J, Craven C, Wabner K, Schmit J, Matter B, Kompella U, Grossniklaus HE, Olsen TW. A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. Investigative Ophthalmology & Visual Science. 58: 3732-3740. PMID 28738417 DOI: 10.1167/Iovs.16-21230 |
0.347 |
|
| 2017 |
Zhang X, Bohner A, Bhuvanagiri S, Uehara H, Upadhyay AK, Emerson LL, Bondalapati S, Muddana SK, Fang D, Li M, Sandhu Z, Hussain A, Carroll LS, Tiem M, Archer B, ... Kompella U, et al. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28236576 DOI: 10.1016/J.Ymthe.2017.01.014 |
0.312 |
|
| 2017 |
Kompella U. Biodegradable implants for sustained drug release: Manufacturing considerations, drug stability, and drug release Acta Ophthalmologica. 95. DOI: 10.1111/J.1755-3768.2017.02143 |
0.338 |
|
| 2016 |
Yavuz B, Kompella UB. Ocular Drug Delivery. Handbook of Experimental Pharmacology. PMID 27783270 DOI: 10.1007/164_2016_84 |
0.402 |
|
| 2016 |
Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W. Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea. Colloids and Surfaces. B, Biointerfaces. 149: 288-296. PMID 27771493 DOI: 10.1016/J.Colsurfb.2016.10.032 |
0.371 |
|
| 2016 |
Kompella U. Nanoparticles for ocular surface drug and gene delivery Acta Ophthalmologica. 94. DOI: 10.1111/J.1755-3768.2016.0394 |
0.329 |
|
| 2016 |
Kompella U. Ocular drug delivery and pharmacokinetics: influence of drug properties and delivery systems Acta Ophthalmologica. 94. DOI: 10.1111/J.1755-3768.2016.0273 |
0.36 |
|
| 2015 |
Malik P, Kadam RS, Cheruvu NP, Kompella UB. Retraction of "Hydrophilic Prodrug Approach for Reduced Pigment Binding and Enhanced Transscleral Retinal Delivery of Celecoxib". Molecular Pharmaceutics. 12: 2558. PMID 26027478 DOI: 10.1021/Acs.Molpharmaceut.5B00366 |
0.321 |
|
| 2015 |
Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB. Retraction of "Hypoxia Alters Ocular Drug Transporter Expression and Activity in Rat and Calf Models: Implications for Drug Delivery", Molecular Pharmaceutics. 12: 2559. DOI: 10.1021/Acs.Molpharmaceut.5B00367 |
0.365 |
|
| 2014 |
Kulkarni SS, Kompella UB. Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma. Journal of Glaucoma. 23: S77-9. PMID 25275914 DOI: 10.1097/Ijg.0000000000000109 |
0.381 |
|
| 2014 |
Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene delivery to the back of the eye: from bench to bedside. Investigative Ophthalmology & Visual Science. 55: 2714-30. PMID 24777644 DOI: 10.1167/Iovs.13-13707 |
0.377 |
|
| 2014 |
Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. Plos One. 9: e87942. PMID 24498227 DOI: 10.1371/Journal.Pone.0087942 |
0.307 |
|
| 2013 |
Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Molecular Pharmaceutics. 10: 4676-86. PMID 24131101 DOI: 10.1021/Mp400487F |
0.379 |
|
| 2013 |
Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB. Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 1151-60. PMID 24075925 DOI: 10.1016/J.Jconrel.2013.09.016 |
0.371 |
|
| 2013 |
Tari SR, Youssif M, Samson CM, Harris RL, Lin CM, Kompella UB, Antonetti DA, Barile GR. Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina. Investigative Ophthalmology & Visual Science. 54: 5550-8. PMID 23882687 DOI: 10.1167/Iovs.13-12144 |
0.328 |
|
| 2013 |
Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Molecular Pharmaceutics. 10: 2858-67. PMID 23734705 DOI: 10.1021/Mp300716T |
0.356 |
|
| 2013 |
Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R. Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. Plos One. 8: e63881. PMID 23667686 DOI: 10.1371/Journal.Pone.0063881 |
0.32 |
|
| 2013 |
Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB. Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery. Molecular Pharmaceutics. 10: 2350-61. PMID 23607566 DOI: 10.1021/Mp3007133 |
0.336 |
|
| 2013 |
Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Progress in Retinal and Eye Research. 36: 172-98. PMID 23603534 DOI: 10.1016/J.Preteyeres.2013.04.001 |
0.78 |
|
| 2013 |
Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. Journal of Controlled Release : Official Journal of the Controlled Release Society. 168: 239-50. PMID 23562638 DOI: 10.1016/J.Jconrel.2013.03.027 |
0.368 |
|
| 2013 |
Kompella UB. Nanotechnology and drug delivery. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 29: 89. PMID 23485089 DOI: 10.1089/Jop.2013.1504 |
0.353 |
|
| 2013 |
Luo L, Zhang X, Hirano Y, Tyagi P, Barabás P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, ... ... Kompella UB, et al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. Acs Nano. 7: 3264-75. PMID 23464925 DOI: 10.1021/Nn305958Y |
0.353 |
|
| 2013 |
Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 29: 236-48. PMID 23256487 DOI: 10.1089/Jop.2012.0210 |
0.314 |
|
| 2013 |
Kadam RS, Vooturi SK, Kompella UB. Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 466-74. PMID 23169611 DOI: 10.1124/Dmd.112.045674 |
0.345 |
|
| 2013 |
Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. British Journal of Clinical Pharmacology. 75: 217-26. PMID 22625877 DOI: 10.1111/J.1365-2125.2012.04343.X |
0.319 |
|
| 2012 |
Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. Plos One. 7: e49635. PMID 23272048 DOI: 10.1371/Journal.Pone.0049635 |
0.311 |
|
| 2012 |
Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 23: 505101. PMID 23186914 DOI: 10.1088/0957-4484/23/50/505101 |
0.529 |
|
| 2012 |
Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. Plos One. 7: e48188. PMID 23118950 DOI: 10.1371/Journal.Pone.0048188 |
0.368 |
|
| 2012 |
Kadam RS, Scheinman RI, Kompella UB. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Molecular Pharmaceutics. 9: 3228-35. PMID 23003570 DOI: 10.1021/Mp300305F |
0.332 |
|
| 2012 |
Vooturi SK, Kadam RS, Kompella UB. Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery. Molecular Pharmaceutics. 9: 3136-46. PMID 23003105 DOI: 10.1021/Mp300245R |
0.389 |
|
| 2012 |
Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. Acs Nano. 6: 7595-606. PMID 22876910 DOI: 10.1021/Nn301873V |
0.378 |
|
| 2012 |
Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicology and Applied Pharmacology. 264: 23-31. PMID 22841772 DOI: 10.1016/J.Taap.2012.07.014 |
0.302 |
|
| 2012 |
Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. International Journal of Pharmaceutics. 434: 140-7. PMID 22633904 DOI: 10.1016/J.Ijpharm.2012.05.025 |
0.367 |
|
| 2012 |
Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1380-8. PMID 22498894 DOI: 10.1124/Dmd.112.044925 |
0.354 |
|
| 2012 |
Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Investigative Ophthalmology & Visual Science. 53: 2837-44. PMID 22467572 DOI: 10.1167/Iovs.11-9139 |
0.57 |
|
| 2012 |
Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Experimental Eye Research. 98: 23-7. PMID 22440812 DOI: 10.1016/J.Exer.2012.03.004 |
0.338 |
|
| 2012 |
Malik P, Kadam RS, Cheruvu NP, Kompella UB. Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Molecular Pharmaceutics. 9: 605-14. PMID 22256989 DOI: 10.1021/Mp2005164 |
0.39 |
|
| 2012 |
Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 776-83. PMID 21930109 DOI: 10.1016/J.Nano.2011.08.018 |
0.614 |
|
| 2011 |
Shelke NB, Kadam R, Tyagi P, Rao VR, Kompella UB. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Delivery and Translational Research. 1: 76-90. PMID 22888471 DOI: 10.1007/S13346-010-0009-8 |
0.394 |
|
| 2011 |
Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvascular Research. 82: 346-50. PMID 21945644 DOI: 10.1016/J.Mvr.2011.09.001 |
0.562 |
|
| 2011 |
Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharmaceutical Research. 28: 2833-47. PMID 21796482 DOI: 10.1007/S11095-011-0532-4 |
0.32 |
|
| 2011 |
Kadam RS, Jadhav G, Ogidigben M, Kompella UB. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1529-37. PMID 21673129 DOI: 10.1124/Dmd.111.040055 |
0.336 |
|
| 2011 |
Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 27: 219-24. PMID 21574814 DOI: 10.1089/Jop.2010.0158 |
0.325 |
|
| 2011 |
Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Archives of Ophthalmology (Chicago, Ill. : 1960). 129: 914-20. PMID 21402977 DOI: 10.1001/Archophthalmol.2011.39 |
0.559 |
|
| 2011 |
Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 771-81. PMID 21346004 DOI: 10.1124/Dmd.110.037408 |
0.608 |
|
| 2011 |
Kadam RS, Cheruvu NP, Edelhauser HF, Kompella UB. Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Investigative Ophthalmology & Visual Science. 52: 5387-99. PMID 21282583 DOI: 10.1167/Iovs.10-6233 |
0.333 |
|
| 2010 |
Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Therapeutic Delivery. 1: 435-56. PMID 21399724 DOI: 10.4155/Tde.10.40 |
0.584 |
|
| 2010 |
Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Investigative Ophthalmology & Visual Science. 51: 5403-20. PMID 20980702 DOI: 10.1167/Iovs.10-5392 |
0.337 |
|
| 2010 |
Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Investigative Ophthalmology & Visual Science. 51: 5804-16. PMID 20484584 DOI: 10.1167/Iovs.10-5388 |
0.327 |
|
| 2010 |
Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Investigative Ophthalmology & Visual Science. 51: 5198-204. PMID 20445119 DOI: 10.1167/Iovs.09-5144 |
0.355 |
|
| 2010 |
Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 26: 137-46. PMID 20415622 DOI: 10.1089/Jop.2009.0132 |
0.743 |
|
| 2010 |
Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (London, England). 5: 485-505. PMID 20394539 DOI: 10.2217/Nnm.10.10 |
0.364 |
|
| 2010 |
Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opinion On Drug Delivery. 7: 631-45. PMID 20205602 DOI: 10.1517/17425241003663236 |
0.769 |
|
| 2010 |
Mayo AS, Ambati BK, Kompella UB. Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. International Journal of Pharmaceutics. 387: 278-85. PMID 20025945 DOI: 10.1016/J.Ijpharm.2009.12.024 |
0.358 |
|
| 2010 |
Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. The Journal of Pharmacology and Experimental Therapeutics. 332: 1107-20. PMID 19926800 DOI: 10.1124/Jpet.109.161570 |
0.35 |
|
| 2010 |
Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Research Bulletin. 81: 327-32. PMID 19761819 DOI: 10.1016/J.Brainresbull.2009.09.001 |
0.793 |
|
| 2009 |
Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7299-308. PMID 19920099 DOI: 10.1158/1078-0432.Ccr-09-1745 |
0.592 |
|
| 2009 |
Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. The British Journal of Ophthalmology. 93: 1387-90. PMID 19628498 DOI: 10.1136/Bjo.2009.157297 |
0.304 |
|
| 2009 |
Sundaram S, Roy SK, Ambati BK, Kompella UB. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 3752-65. PMID 19608628 DOI: 10.1096/Fj.09-129825 |
0.564 |
|
| 2009 |
Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Investigative Ophthalmology & Visual Science. 50: 4887-97. PMID 19516015 DOI: 10.1167/Iovs.09-3565 |
0.301 |
|
| 2009 |
Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Molecular Cancer Therapeutics. 8: 1655-65. PMID 19509261 DOI: 10.1158/1535-7163.Mct-08-0988 |
0.541 |
|
| 2009 |
Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 58: 1902-13. PMID 19491211 DOI: 10.2337/Db08-1327 |
0.351 |
|
| 2009 |
Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 25: 97-103. PMID 19284324 DOI: 10.1089/Jop.2008.0090 |
0.708 |
|
| 2009 |
Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharmaceutical Research. 26: 1155-61. PMID 19194787 DOI: 10.1007/S11095-009-9835-0 |
0.341 |
|
| 2009 |
Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Therapy. 16: 645-59. PMID 19194480 DOI: 10.1038/Gt.2008.185 |
0.603 |
|
| 2009 |
Sundaram S, Roy SK, Kompella UB. Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides. 30: 351-8. PMID 18992782 DOI: 10.1016/J.Peptides.2008.10.005 |
0.545 |
|
| 2009 |
Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. Pharmaceutical Research. 26: 404-14. PMID 18987961 DOI: 10.1007/S11095-008-9757-2 |
0.756 |
|
| 2009 |
Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharmaceutical Research. 26: 1236-60. PMID 18841448 DOI: 10.1007/S11095-008-9728-7 |
0.335 |
|
| 2009 |
Singh SR, Kompella UB. Nanotechnology for Gene Delivery to the Eye European Ophthalmic Review. 3: 7. DOI: 10.17925/Eor.2009.03.01.7 |
0.556 |
|
| 2008 |
Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Molecular Vision. 14: 150-60. PMID 18334929 |
0.788 |
|
| 2008 |
Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Investigative Ophthalmology & Visual Science. 49: 333-41. PMID 18172110 DOI: 10.1167/Iovs.07-0214 |
0.768 |
|
| 2008 |
Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Investigative Ophthalmology & Visual Science. 49: 320-32. PMID 18172109 DOI: 10.1167/Iovs.07-0593 |
0.768 |
|
| 2008 |
Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. The Journal of Pharmacology and Experimental Therapeutics. 324: 749-58. PMID 18032574 DOI: 10.1124/Jpet.107.128918 |
0.768 |
|
| 2007 |
Raghava S, Kompella UB. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. European Journal of Pharmacology. 568: 68-74. PMID 17543940 DOI: 10.1016/J.Ejphar.2007.04.044 |
0.361 |
|
| 2007 |
Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 23: 116-23. PMID 17444799 DOI: 10.1089/Jop.2006.0112 |
0.761 |
|
| 2007 |
Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit. Expert Opinion On Drug Delivery. 4: 77-85. PMID 17184164 DOI: 10.1517/17425247.4.1.77 |
0.713 |
|
| 2007 |
Kompella UB. Nanotechnology for drug and gene delivery to the eye Nanomedicine: Nanotechnology, Biology and Medicine. 3: 342. DOI: 10.4172/2155-9570.S1.03 |
0.35 |
|
| 2006 |
Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Molecular Vision. 12: 1185-98. PMID 17102798 |
0.526 |
|
| 2006 |
Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Investigative Ophthalmology & Visual Science. 47: 4513-22. PMID 17003447 DOI: 10.1167/Iovs.06-0404 |
0.309 |
|
| 2006 |
Margalit E, Kugler LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, Christensen GR. The safety of intraocular ketorolac in rabbits. Investigative Ophthalmology & Visual Science. 47: 2093-9. PMID 16639020 DOI: 10.1167/Iovs.05-0764 |
0.309 |
|
| 2006 |
Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Investigative Ophthalmology & Visual Science. 47: 1149-60. PMID 16505053 DOI: 10.1167/Iovs.05-0531 |
0.794 |
|
| 2005 |
Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. The Journal of Pharmacy and Pharmacology. 57: 1555-63. PMID 16354399 DOI: 10.1211/Jpp.57.12.0005 |
0.746 |
|
| 2005 |
Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. The Journal of Pharmacy and Pharmacology. 57: 851-60. PMID 15969944 DOI: 10.1211/0022357056334 |
0.786 |
|
| 2005 |
Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. European Journal of Pharmacology. 511: 191-8. PMID 15792788 DOI: 10.1016/J.Ejphar.2005.02.019 |
0.744 |
|
| 2005 |
Dhanda DS, Kompella UB. Metered dose inhalers (MDIs) and dry powder inhalers (DPIs) for pulmonary drug delivery: CMC issues Clinical Research and Regulatory Affairs. 22: 31-55. DOI: 10.1081/Crp-62268 |
0.339 |
|
| 2004 |
Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opinion On Drug Delivery. 1: 99-114. PMID 16296723 DOI: 10.1517/17425247.1.1.99 |
0.406 |
|
| 2004 |
Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharmaceutical Research. 21: 1797-804. PMID 15553225 DOI: 10.1023/B:Pham.0000045231.51924.E8 |
0.733 |
|
| 2004 |
Bandi N, Wei W, Roberts CB, Kotra LP, Kompella UB. Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 23: 159-68. PMID 15451004 DOI: 10.1016/J.Ejps.2004.06.007 |
0.72 |
|
| 2004 |
Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. European Journal of Pharmacology. 498: 275-8. PMID 15364005 DOI: 10.1016/J.Ejphar.2004.07.046 |
0.781 |
|
| 2004 |
Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharmaceutical Research. 21: 1119-26. PMID 15290850 DOI: 10.1023/B:Pham.0000032997.96823.88 |
0.725 |
|
| 2004 |
Koushik KN, Kompella UB. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. The Journal of Pharmacy and Pharmacology. 56: 861-8. PMID 15233864 DOI: 10.1211/0022357023646 |
0.724 |
|
| 2004 |
Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharmaceutical Research. 21: 1034-46. PMID 15212170 DOI: 10.1023/B:Pham.0000029294.70707.74 |
0.754 |
|
| 2004 |
Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharmaceutical Research. 21: 524-35. PMID 15070105 DOI: 10.1023/B:Pham.0000019308.25479.A4 |
0.728 |
|
| 2004 |
Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. The Journal of Pharmacy and Pharmacology. 56: 351-8. PMID 15025860 DOI: 10.1211/0022357022908 |
0.778 |
|
| 2004 |
Amrite AC, Cheruvu NPS, Sundaram S, Aravalli RN, Cheng PW, Kompella UB. Lung gene therapy: Clinical and regulatory issues Clinical Research and Regulatory Affairs. 21: 1-28. DOI: 10.1081/Crp-120039559 |
0.75 |
|
| 2004 |
Sundaram S, Bontha S, Koushik K, Kompella UB. Nasal and pulmonary delivery of deslorrelin, a peptide drug American Pharmaceutical Review. 7: 130-139. |
0.747 |
|
| 2003 |
Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. The Journal of Pharmacy and Pharmacology. 55: 1199-206. PMID 14604462 DOI: 10.1211/0022357021701 |
0.799 |
|
| 2003 |
Koushik K, Sunkara G, Gwilt P, Kompella UB. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharmaceutical Research. 20: 779-87. PMID 12751634 DOI: 10.1023/A:1023489620394 |
0.758 |
|
| 2003 |
Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Investigative Ophthalmology & Visual Science. 44: 1192-201. PMID 12601049 DOI: 10.1167/Iovs.02-0791 |
0.804 |
|
| 2003 |
Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. European Journal of Pharmacology. 458: 283-9. PMID 12504784 DOI: 10.1016/S0014-2999(02)02793-0 |
0.727 |
|
| 2002 |
Martin TM, Bandi N, Shulz R, Roberts CB, Kompella UB. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. Aaps Pharmscitech. 3: E18. PMID 12916933 DOI: 10.1007/Bf02830616 |
0.73 |
|
| 2002 |
Wenzel JG, Balaji KS, Koushik K, Navarre C, Duran SH, Rahe CH, Kompella UB. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. Journal of Controlled Release : Official Journal of the Controlled Release Society. 85: 51-9. PMID 12480311 DOI: 10.1016/S0168-3659(02)00271-7 |
0.743 |
|
| 2002 |
Ayalasomayajula SP, Kompella UB. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. European Journal of Pharmacology. 449: 213-20. PMID 12167462 DOI: 10.1016/S0014-2999(02)02043-5 |
0.716 |
|
| 2002 |
Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharmaceutical Research. 19: 278-85. PMID 11934234 DOI: 10.1023/A:1014438800893 |
0.767 |
|
| 2002 |
Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). European Journal of Pharmacology. 437: 9-17. PMID 11864633 DOI: 10.1016/S0014-2999(02)01267-0 |
0.71 |
|
| 2002 |
Wenzel JGW, Balaji KSS, Koushik K, Navarre C, Duran SH, Rahe CH, Kompella UB. Pluronic® F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle Journal of Controlled Release. 85: 51-59. DOI: 10.1016/S0168-3659(02)00271-7 |
0.727 |
|
| 2001 |
Sunkara G, Kompella UB. Controlled release of bioactive materials--28th international symposium. Carbohydrate drug carriers: cyclodextrins and chitosans. Idrugs : the Investigational Drugs Journal. 4: 1014-6. PMID 15965845 |
0.6 |
|
| 2001 |
Koushik KN, Bandi N, Kompella UB. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin. Pharmaceutical Development and Technology. 6: 595-606. PMID 11775960 DOI: 10.1081/Pdt-120000297 |
0.754 |
|
| 2001 |
Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. European Journal of Pharmacology. 425: 109-16. PMID 11502275 DOI: 10.1016/S0014-2999(01)01192-X |
0.724 |
|
| 2001 |
Aukunuru JV, Sunkara G, Bandi N, Thoreson WB, Kompella UB. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharmaceutical Research. 18: 565-72. PMID 11465409 DOI: 10.1023/A:1011060705599 |
0.77 |
|
| 2001 |
Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Critical Reviews in Therapeutic Drug Carrier Systems. 18: 173-99. PMID 11325031 DOI: 10.1615/Critrevtherdrugcarriersyst.V18.I2.20 |
0.743 |
|
| 2000 |
Ayalasomayajula SP, Kompella UB. Drug efflux pumps: challenges and opportunities. 14-18 November 1999, New Orleans, LA, USA. Idrugs : the Investigational Drugs Journal. 3: 148-9. PMID 16107925 |
0.69 |
|
| 2000 |
Sunkara G, Deruiter J, Clark CR, Kompella UB. In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor. The Journal of Pharmacy and Pharmacology. 52: 1113-22. PMID 11045892 DOI: 10.1211/0022357001774877 |
0.638 |
|
| 2000 |
Aukunuru JV, Kompella UB, Betageri GV. Simultaneous high performance liquid chromatographic analysis of acetaminophen, salicylamide, phenyltoloxamine, and related products Journal of Liquid Chromatography and Related Technologies. 23: 565-578. DOI: 10.1081/Jlc-100101473 |
0.717 |
|
| 1999 |
Kompella UB, Sunkara G, Thomas E, Clark CR, Deruiter J. Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines. The Journal of Pharmacy and Pharmacology. 51: 921-7. PMID 10504031 DOI: 10.1211/0022357991773357 |
0.625 |
|
| 1999 |
Sunkara G, Navarre CB, Kompella UB. Influence of pH and temperature on kinetics of ceftiofur degradation in aqueous solutions. The Journal of Pharmacy and Pharmacology. 51: 249-55. PMID 10344624 DOI: 10.1211/0022357991772411 |
0.595 |
|
| 1999 |
Navarre CB, Zhang L, Sunkara G, Duran SH, Kompella UB. Ceftiofur distribution in plasma and joint fluid following regional limb injection in cattle. Journal of Veterinary Pharmacology and Therapeutics. 22: 13-9. PMID 10211712 DOI: 10.1046/J.1365-2885.1999.00186.X |
0.614 |
|
| 1999 |
Kompella UB, Aukunuru JV, Betageri GV. Effect of neutral liposomes on corneal and conjunctival transport of didanosine Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents. 6: 9-14. DOI: 10.1080/107175499267101 |
0.765 |
|
| 1998 |
Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? Journal of Drug Targeting. 5: 415-41. PMID 9783675 DOI: 10.3109/10611869808997870 |
0.301 |
|
| 1998 |
Kompella UB, Katragadda AK, Aukunuru JV, Betageri GV. Effect of liposomal charge on stavudine transport across rabbit cornea and conjunctiva Pharmacy and Pharmacology Communications. 4: 339-343. DOI: 10.1111/J.2042-7158.1998.Tb00708.X |
0.761 |
|
| 1996 |
Kompella UB, Dani BA. Metabolism of [Des-Gly10, D-Trp6]LHRH ethylamide in rabbit nasal tissue Life Sciences. 58: 2201-2207. PMID 8649206 DOI: 10.1016/0024-3205(96)00214-7 |
0.302 |
|
| 1995 |
Kompella UB, Kim KJ, Shiue MH, Lee VH. Possible existence of Na(+)-coupled amino acid transport in the pigmented rabbit conjunctiva. Life Sciences. 57: 1427-31. PMID 7674833 DOI: 10.1016/0024-3205(95)02105-R |
0.746 |
|
| 1993 |
Lee YH, Kompella UB, Lee VH. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. Experimental Eye Research. 57: 341-9. PMID 7901046 DOI: 10.1006/Exer.1993.1133 |
0.506 |
|
| Show low-probability matches. |
